Palliative Medicine, Royal Marsden Hospital, Sutton, Surrey, UK.
Eur J Cancer Care (Engl). 2010 Mar;19(2):172-7. doi: 10.1111/j.1365-2354.2009.01081.x. Epub 2009 Aug 31.
A group of interested professionals was convened to develop some evidence-based recommendations on the management of salivary gland dysfunction (SGD) in oncology patients. A Medline search was performed to identify the literature on SGD. The abstracts of all identified papers were read, and the full texts of all relevant papers were reviewed. The evidence was graded according to the Scottish Intercollegiate Guidelines Network grading system for recommendations in evidence-based guidelines. The summary of the main recommendations are: (1) patients with cancer should be regularly assessed for SGD (grade of recommendation - D); (2) the management of SGD should be individualised (D); (3) consideration should be given to strategies to prevent the development of radiation-induced SGD (C); (4) consideration should be given to treatment of the cause(s) of the SGD (C); (5) the treatment of choice for the symptomatic management of SGD is use of an appropriate saliva stimulant (C); (6) consideration should be given to prevention of the complications of the SGD (D); (7) consideration should be given to treatment of the complications of the SGD (D); and (8) patients with SGD should be regularly reassessed (D).
一组相关专业人员聚集在一起，制定了一些基于证据的建议，以管理肿瘤患者的唾液腺功能障碍（SGD）。进行了 Medline 搜索以确定有关 SGD 的文献。阅读了所有确定的论文摘要，并审查了所有相关论文的全文。根据苏格兰校际指南网络分级系统对基于证据的指南中的建议进行了分级。主要建议摘要如下：（1）应定期评估癌症患者的 SGD（推荐等级-D）；（2）SGD 的管理应个体化（D）；（3）应考虑采取策略预防放射性 SGD 的发展（C）；（4）应考虑治疗 SGD 的原因（C）；（5）治疗 SGD 症状的首选方法是使用适当的唾液刺激剂（C）；（6）应考虑预防 SGD 的并发症（D）；（7）应考虑治疗 SGD 的并发症（D）；以及（8）应定期重新评估 SGD 患者（D）。
